fda approval bpc-157 This is the first vote from the FDA's Pharmacy Compounding Advisory Committee on one of 7 peptides up for consideration. While the committee advises through these votes, ultimately the will make FDA Peptide Compounding Vote 2026:

Key safety principles include: Never share syringes, needles, or vials with another person Always use a new, sterile syringe for each injection Maintain strict hand hygiene and site cleaning protocols Store and dispose of sharps according to local regulations Don't inject into areas with visible infection, inflammation, rashes, or moles Contact your physician if you notice signs of infection at an injection site (increasing redness, warmth, swelling, or discharge) AOD-9604 itself has a well-established safety profile at therapeutic doses

Committee members nevertheless voted to recommend inclusion after considering available data as well as testimony from physicians, compounders and patients who argued that the peptide fulfills an unmet clinical need

Sadati can address that and any other questions during a consultation

You cannot simply use a product from a hardware store